High-Risk Patients Awaiting Liver Transplant Benefit Most From Living Donors
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
WEDNESDAY, Oct. 11, 2023 -- High-risk cirrhosis patients awaiting liver transplant (LT) most benefit from potential living donors, according to a study published online Sept. 2 in Aging.
Fakhar Ali Qazi Arisar, M.B.B.S., from the University of Toronto, and colleagues evaluated the impact of access to living donor liver transplantation (LDLT) in wait-listed patients at highest risk for dropout. The analysis included 860 adult patients with decompensated cirrhosis listed for LT from November 2012 to December 2018.
The researchers found that 41.8 percent had a potential living donor identified and 57.6 percent underwent LT, 34.2 percent of which were LDLT. The benefit of a potential living donor was most evident for patients with moderate-to-severe frailty at listing, height <160 cm, and Model for End-Stage Liver Disease (MELD)-Na score <20. Patients at highest risk for dropout while waiting for a deceased donor most benefited from a potential living donor (time-dependent area under the receiver operating characteristic curve, 0.82).
"Our study identifies that certain patient subgroups (short stature, MELD <20, and moderate-to-severe frailty) are at the highest risk for waitlist mortality with prolonged waiting time for a deceased donor organ offer," the authors write. "These patient subgroups, which represent a growing share of the waitlist population in recent years, would be especially protected against death or delisting if they had access to living donation at the time of listing. Certainly, LDLT is beneficial to all, with improved waitlist mortality and posttransplant outcomes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Semaglutide Alleviates Metabolic-Linked Liver Disease in People With HIV
TUESDAY, April 30, 2024 -- For people with HIV (PWH), semaglutide is effective for metabolic dysfunction-associated steatotic liver disease (MASLD), according to a research letter...
Prevalence of Hepatitis Delta High in Hepatitis B Surface Antigen Chronic Carriers
THURSDAY, April 4, 2024 -- The prevalence of hepatitis delta virus (HDV) is high in hepatitis B surface antigen (HBs Ag) chronic carriers detected through annual screenings...
Heart Transplant Offer Acceptance Highest for White Women
TUESDAY, March 26, 2024 -- The cumulative incidence of heart transplant offer acceptance is highest for White women, according to a study published online March 25 in the Journal...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.